Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
17/05/2021 | 22:07 | Edgar (US Regulatory) | Amended Current Report Filing (8-k/a) | NASDAQ:ABCL | AbCellera Biologics Inc |
15/05/2021 | 02:48 | Business Wire | CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
14/05/2021 | 22:07 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ABCL | AbCellera Biologics Inc |
13/05/2021 | 22:05 | Business Wire | AbCellera Reports Q1 2021 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
11/05/2021 | 22:05 | Business Wire | AbCellera to Present Virtually at Berenberg Conference on May 18, 2021 | NASDAQ:ABCL | AbCellera Biologics Inc |
06/05/2021 | 15:00 | Business Wire | AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy | NASDAQ:ABCL | AbCellera Biologics Inc |
04/05/2021 | 12:30 | Business Wire | New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials | NASDAQ:ABCL | AbCellera Biologics Inc |
29/04/2021 | 22:10 | Business Wire | AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals | NASDAQ:ABCL | AbCellera Biologics Inc |
28/04/2021 | 22:04 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:ABCL | AbCellera Biologics Inc |
21/04/2021 | 22:05 | Business Wire | AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021 | NASDAQ:ABCL | AbCellera Biologics Inc |
14/04/2021 | 22:05 | Business Wire | AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration | NASDAQ:ABCL | AbCellera Biologics Inc |
12/04/2021 | 22:05 | Business Wire | AbCellera to Present Virtually at Upcoming Investor Conferences | NASDAQ:ABCL | AbCellera Biologics Inc |
05/04/2021 | 20:00 | Business Wire | Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 & Support its Use as a Foundational... | NASDAQ:ABCL | AbCellera Biologics Inc |
01/04/2021 | 16:37 | Dow Jones News | AbCellera Biologics Up; Expands Agreement With Gilead | NASDAQ:ABCL | AbCellera Biologics Inc |
01/04/2021 | 15:00 | Business Wire | AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration | NASDAQ:ABCL | AbCellera Biologics Inc |
01/04/2021 | 13:49 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ABCL | AbCellera Biologics Inc |
31/03/2021 | 00:07 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:ABCL | AbCellera Biologics Inc |
29/03/2021 | 22:05 | Business Wire | AbCellera Reports Full Year 2020 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
10/03/2021 | 18:32 | Dow Jones News | AbCellera Posts Positive Results For Advanced Covid-19 Treatment Trial | NASDAQ:ABCL | AbCellera Biologics Inc |
10/03/2021 | 17:21 | Business Wire | AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations & Prevented Death in Phase 3 Trial for Ea... | NASDAQ:ABCL | AbCellera Biologics Inc |
05/03/2021 | 23:00 | Dow Jones News | AbCellera's Covid-19 Treatment Gets Recommendation From European Regulators | NASDAQ:ABCL | AbCellera Biologics Inc |
05/03/2021 | 21:30 | Business Wire | EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients | NASDAQ:ABCL | AbCellera Biologics Inc |
17/02/2021 | 22:05 | Business Wire | AbCellera to Present at the SVB Leerink Global Healthcare Conference | NASDAQ:ABCL | AbCellera Biologics Inc |
16/02/2021 | 22:38 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:ABCL | AbCellera Biologics Inc |
16/02/2021 | 12:38 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ABCL | AbCellera Biologics Inc |
11/02/2021 | 22:05 | Business Wire | AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer | NASDAQ:ABCL | AbCellera Biologics Inc |
10/02/2021 | 02:26 | Business Wire | AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19 | NASDAQ:ABCL | AbCellera Biologics Inc |
03/02/2021 | 22:05 | Business Wire | AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call | NASDAQ:ABCL | AbCellera Biologics Inc |
27/01/2021 | 13:22 | Business Wire | AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19 | NASDAQ:ABCL | AbCellera Biologics Inc |
26/01/2021 | 13:09 | Business Wire | AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations & Death b... | NASDAQ:ABCL | AbCellera Biologics Inc |